News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Genentech in collaboration to explore Avastin for brain cancer treatment


Posted on: 10/20/2005

Genentech in collaboration to explore Avastin for brain cancer treatment

AFX News Limited

10.20.2005, 02:29 AM

BURLINGAME, Calif (AFX) - Genentech Inc said it has entered into a collaboration with Accelerate Brain Cancer Cure (ABC 2), a non-profit foundation, to explore the potential of Avastin for treating patients with glioblastoma multiforme (GBM), an especially deadly form of brain cancer.

The collaboration is focused on a novel imaging study of patients with recurrent GBM who are enrolled in a Phase II clinical trial at Duke University. The two parties will initially share development expenses and if the results are successful, ABC (2) will provide access to its resources for a Genentech-sponsored randomized clinical trial in relapsed GBM.

'Encouraging preliminary data from early-stage research of Avastin in glioblastoma multiforme led us to initiate a Phase II study to gain further insight into Avastin's potential role in this setting,' said Gwen Fyfe, Genentech's vice president of Clinical Hematology/Oncology.

newsdesk@afxnews.com ak/


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740